Get the Stockscreener App
8.14
2.01%
0.16
Mink Therapeutics Inc stock is traded at $8.14, with a volume of 645.
It is up +2.01% in the last 24 hours and down -14.29% over the past month.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.
See More
Previous Close:
$7.98
Open:
$8.37
24h Volume:
645
Relative Volume:
0.02
Market Cap:
$31.63M
Revenue:
-
Net Income/Loss:
$-24.77M
P/E Ratio:
-11.15
EPS:
-0.73
Net Cash Flow:
$-17.36M
1W Performance:
-0.73%
1M Performance:
-14.29%
6M Performance:
+4.96%
1Y Performance:
-8.54%
1-Day Range:
$8.37
$8.37
1-Week Range:
$7.54
$8.50
52-Week Range:
$4.5601
$19.00
Mink Therapeutics Inc Stock (INKT) Company Profile
Name
Mink Therapeutics Inc
Sector
Industry
Phone
212-994-8250
Address
149 FIFTH AVENUE, NEW YORK
Compare INKT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INKT
Mink Therapeutics Inc
|
8.37 | 31.63M | 0 | -24.77M | -17.36M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
507.77 | 130.68B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
679.18 | 74.97B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.43 | 36.08B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.07 | 31.19B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
256.51 | 27.56B | 3.32B | -860.46M | -1.04B | -8.32 |
Mink Therapeutics Inc Stock (INKT) Latest News
Mink Therapeutics Inc expected to post a loss of 50 cents a shareEarnings Preview - TradingView
MiNK Therapeutics (INKT) Projected to Post Earnings on Tuesday - Defense World
New Strong Buy Stocks for July 11th - MSN
The Future of Refractory Multiple Myeloma Therapy: 75+ - openPR
MiNK Therapeutics, Inc. to Announce Fourth Quarter and Year End 2024 Financial Results on March 18th - Nasdaq
MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report - GlobeNewswire
When Will MiNK Therapeutics Reveal Its 2024 Financial Performance? - StockTitan
What is HC Wainwright’s Estimate for INKT Q1 Earnings? - Defense World
Brokers Set Expectations for INKT FY2029 Earnings - Defense World
MiNK Therapeutics stock target soars to $35 at H.C. Wainwright By Investing.com - Investing.com South Africa
MiNK Therapeutics stock target soars to $35 at H.C. Wainwright - Investing.com India
MiNK Therapeutics presents allo-iNKTs combination data in 2L gastric cancer - TipRanks
MiNK Therapeutics Presents First-in-Kind Allo-iNKTs - GlobeNewswire
MiNK Therapeutics Presents Promising Data from Phase 2 Study of Allo-iNKT Cell Therapy AgenT-797 at AACR Meeting - Nasdaq
MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting - The Manila Times
Can This Novel Cancer Therapy Revolutionize Gastric Cancer Treatment? New Clinical Data Reveals Answer - StockTitan
How the (INKT) price action is used to our Advantage - Stock Traders Daily
MiNK Therapeutics regains Nasdaq compliance By Investing.com - Investing.com Nigeria
MiNK Therapeutics Announces Regained Compliance With Nasdaq Listing Requirements - Nasdaq
MiNK Therapeutics regains Nasdaq compliance - Investing.com India
Tango Therapeutics to Present at Three Upcoming Investment Bank Conferences - The Manila Times
MiNK Therapeutics Regains Compliance with Nasdaq Listing Requirements - Nasdaq
MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements - GlobeNewswire
Can MiNK Therapeutics' Nasdaq Compliance Victory Signal a Turnaround for iNKT Cell Therapy Pioneer? - StockTitan
Stocks Surge Across Health Services and Industry Sectors: Nuvve, Exagen, and Flexsteel Lead the Way - HPBL
(INKT) Trading Advice - Stock Traders Daily
Mink Therapeutics Inc Stock (INKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.28%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):